Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wulf

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Nature Communications|December 11, 2023
Retraction Note: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancerJeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2022
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerFelipe Batalini, Niya Xiong, Nabihah Tayob, et al.
Nature Communications|March 14, 2023
Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancerJeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, et al.
The Journal of Clinical Investigation|December 15, 2021
WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer modelsTakahiro Kishikawa, Hiroshi Higuchi, Limei Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2016
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletionAshish Juvekar, Hai Hu, Sina Yadegarynia, et al.
Cancer Research Communications|May 8, 2024
Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft ModelsZhanfang Guo, Jingqin Luo, R Jay Mashl, et al.
Nature Communications|March 21, 2020
Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancerQingjian Li, Tao Qin, Zhuofei Bi, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancerAdrienne G Waks, Tanya E Keenan, Tianyu Li, et al.
Cancer Discovery|August 24, 2012
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancerAshish Juvekar, Laura N Burga, Hai Hu, et al.
Cancer Discovery|April 25, 2019
PARP Inhibitor Efficacy Depends on CD8<sup>+</sup> T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast CancerConstantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Nature Communications|December 11, 2023
Retraction Note: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancerJeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2022
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerFelipe Batalini, Niya Xiong, Nabihah Tayob, et al.
Nature Communications|March 14, 2023
Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancerJeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, et al.
The Journal of Clinical Investigation|December 15, 2021
WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer modelsTakahiro Kishikawa, Hiroshi Higuchi, Limei Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 13, 2016
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletionAshish Juvekar, Hai Hu, Sina Yadegarynia, et al.
Cancer Research Communications|May 8, 2024
Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft ModelsZhanfang Guo, Jingqin Luo, R Jay Mashl, et al.
Nature Communications|March 21, 2020
Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancerQingjian Li, Tao Qin, Zhuofei Bi, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancerAdrienne G Waks, Tanya E Keenan, Tianyu Li, et al.
Cancer Discovery|August 24, 2012
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancerAshish Juvekar, Laura N Burga, Hai Hu, et al.
Cancer Discovery|April 25, 2019
PARP Inhibitor Efficacy Depends on CD8<sup>+</sup> T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast CancerConstantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, et al.
Pageof 16